Results 81 to 90 of about 89,537 (296)
Research progress on tofacitinib in the treatment of chronic actinic dermatitis
Pifu-xingbing zhenliaoxue zazhiChronic actinic dermatitis (CAD) is a group of immune-mediated diseases characterized by photosensitivity. Tofacitinib, a Janus kinase (JAK) 1/3 inhibitor, is currently the most extensively reported and widely used JAK inhibitor for the treatment of CAD.
WU Hui +5 more
doaj +1 more source
Immunotargets and Therapy for Prurigo Nodularis
ImmunoTargets and Therapy, 2022 Angelina Labib, Teresa Ju, Ashley Vander Does, Gil Yosipovitch Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery and Miami Itch Center, University of Miami Miller School of Medicine, Miami, FL, USACorrespondence: Gil Yosipovitch, Dr ...
Labib A +3 more
doaj
In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)
BMC Rheumatology, 2018 Background Anti-cytokine therapies such as adalimumab, tocilizumab, and the small molecule JAK inhibitor tofacitinib have proven that cytokines and their subsequent downstream signaling processes are important in the pathogenesis of rheumatoid arthritis.
Julie M. Parmentier +13 more
doaj +1 more source
Selective JAK-Inhibitors in Spondyloarthritis
Mediterranean Journal of RheumatologyAs our research interest and knowledge increases in the field of Spondyloarthritis, new aspects also emerge as regards to their therapeutic approach. JAK inhibitors (JAKi) are a relatively new treatment option, aiming molecules in the JAK-STAT pathway, which has a leading role in the pathophysiology of both Psoriatic Arthritis and Axial ...
Vassilakis, Konstantinos D. +3 more
openaire +3 more sources
Inhibitor-based affinity probes for the investigation of JAK signaling pathways
, 2015 Hoefener M, Pachl F, Kuster B, Sewald N. Inhibitor-based affinity probes for the investigation of JAK signaling pathways. PROTEOMICS. 2015;15(17):3066-3074.The Janus Kinase (JAK) signaling pathway plays a key role for many cellular processes and has ...
Pachl, Fiona +7 more
core +1 more source
Structural insights into an engineered feruloyl esterase with improved MHET degrading properties
FEBS Letters, EarlyView.A feruloyl esterase was engineered to mimic key features of MHETase, enhancing the degradation of PET oligomers. Structural and computational analysis reveal how a point mutation stabilizes the active site and reshapes the binding cleft, expading substrate scope.
Panagiota Karampa +5 more
wiley +1 more source
Gut microbiome and aging—A dynamic interplay of microbes, metabolites, and the immune system
FEBS Letters, EarlyView.Age‐dependent shifts in microbial communities engender shifts in microbial metabolite profiles. These in turn drive shifts in barrier surface permeability of the gut and brain and induce immune activation. When paired with preexisting age‐related chronic inflammation this increases the risk of neuroinflammation and neurodegenerative diseases.
Aaron Mehl, Eran Blacher
wiley +1 more source
Buying into JAK Inhibitors [PDF]
Cancer Discovery, 2013 Abstract Gilead Sciences of Foster City, CA, has offered $510 million for YM BioSciences of Mississauga, Ontario, Canada, whose primary product, CYT387, is an early-stage JAK1 and JAK 2 inhibitor.
openaire +1 more source
FEBS Letters, EarlyView.Biomolecular condensates formed by fused in sarcoma (FUS) are dissolved by high ATP concentrations yet persist in cells. Using a reconstituted system, we demonstrate that valosin‐containing protein (VCP), an AAA+ ATPase, counteracts ATP‐driven dissolution of FUS condensates through its D2 ATPase activity.
Hitomi Kimura +2 more
wiley +1 more source